How are treatment decisions evolving in pancreatic cancer? Explore real-world challenges, emerging therapies, and multidisciplinary strategies in advanced disease.
6 questions
Correct Answer: C
Most patients present with advanced disease due to nonspecific symptoms and lack of screening, which continues to shape treatment strategy and outcomes.
https://www.nature.com/articles/s41392-025-02499-y
A fit patient (ECOG 1) with metastatic pancreatic cancer is eligible for multi-agent chemotherapy. In practice, what often drives the choice between regimens?
While multiple systemic regimens are available, real-world treatment selection is often guided by tolerability, comorbidities, and patient goals, given the toxicity burden associated with combination therapies.
Treatment-related toxicity frequently necessitates dose adjustments or regimen modification in pancreatic cancer, reflecting the need to balance disease control with quality of life.
Despite advances in systemic therapy, which challenge continues to limit outcomes in advanced pancreatic cancer?
Survival outcomes remain modest in pancreatic cancer, and cumulative toxicity often limits sustained treatment benefit, reinforcing the need for new therapeutic strategies.
For therapies that require sustained or continuous use, patient selection is critical. Factors such as ability to adhere to treatment schedules, manage practical aspects of therapy, and integrate it into daily routines directly influence real-world effectiveness.
https://pubmed.ncbi.nlm.nih.gov/39401002/
When incorporating emerging device-based therapies into pancreatic cancer management, how are these approaches most appropriately integrated into clinical practice?
Correct Answer: D
Emerging approaches are being explored alongside standard systemic treatment rather than replacing it. Their use may require coordination across oncology care teams to support treatment delivery, manage tolerability, and optimize adherence.